1. Home
  2. YSG vs CMPX Comparison

YSG vs CMPX Comparison

Compare YSG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$4.37

Market Cap

889.0M

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.09

Market Cap

752.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
CMPX
Founded
2016
2014
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.0M
752.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
YSG
CMPX
Price
$4.37
$5.09
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$13.44
AVG Volume (30 Days)
336.9K
1.9M
Earning Date
11-17-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$571,300,568.00
N/A
Revenue This Year
$28.96
N/A
Revenue Next Year
$16.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.59
N/A
52 Week Low
$3.01
$1.33
52 Week High
$11.57
$5.86

Technical Indicators

Market Signals
Indicator
YSG
CMPX
Relative Strength Index (RSI) 29.73 52.34
Support Level $3.30 $5.09
Resistance Level $5.73 $5.44
Average True Range (ATR) 0.42 0.34
MACD -0.12 -0.07
Stochastic Oscillator 33.91 31.42

Price Performance

Historical Comparison
YSG
CMPX

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: